Zydus completes MASH study and gains India Phase III clearance

Zydus completed the global Phase II(b) EVIDENCES-X clinical trial of Saroglitazar Magnesium in metabolic dysfunction-associated steatohepatitis, or MASH, and received Indian regulatory approval to start Phase III trials of one monoclonal antibody. The update also included new Phase III analysis in primary biliary cholangitis, or PBC, presented at the American College of Gastroenterology 2026 Annual Meeting.

What did Zydus report on Saroglitazar research?

Zydus reported two Saroglitazar Magnesium developments in its innovation update: completion of the EVIDENCES-X global Phase II(b) trial in MASH and presentation of a new analysis from a Phase III PBC trial at the American College of Gastroenterology, or ACG, 2026 Annual Meeting. These are separate disease indications and separate clinical-development stages for the same molecule.

The reported progression differs by programme. The MASH study has completed Phase II(b), while the PBC programme had Phase III clinical-trial data available for a new analysis in 2026. Zydus did not disclose patient numbers, treatment duration, efficacy results, safety results, regulatory submission timing, or next development steps for either Saroglitazar Magnesium programme in the supplied update.

What does completion of the EVIDENCES-X MASH trial mean?

Completion means Zydus has finished the EVIDENCES-X global Phase II(b) clinical trial in MASH, according to the presentation. Phase II(b) is the trial stage expressly identified by Zydus; the document does not state whether the trial met any endpoints, what comparator it used, or whether the company plans to move Saroglitazar Magnesium into Phase III testing for MASH.

MASH is one of two Saroglitazar Magnesium indications highlighted in the update, alongside PBC. Zydus also states on its company overview page that Bilypsa, identified as Saroglitazar, is the first approved product for MASH in India. That commercial-status statement concerns Bilypsa in India, whereas EVIDENCES-X is described as a global Phase II(b) clinical trial of Saroglitazar Magnesium.

What new PBC information did Zydus present?

Zydus presented a new analysis from a Phase III clinical trial of Saroglitazar Magnesium in PBC at the ACG 2026 Annual Meeting. PBC is primary biliary cholangitis, and the presentation identifies the evidence as an analysis from an existing Phase III trial rather than announcing completion of a new PBC study.

The PBC update is more advanced in trial phase than the completed MASH Phase II(b) trial: Phase III versus Phase II(b). However, the supplied material gives no numerical clinical outcomes, statistical measures, patient population details, or regulatory decisions for the PBC programme. The significance disclosed is the 2026 scientific-meeting presentation of an additional analysis, not a stated approval or filing.

Which monoclonal antibody can enter Phase III trials in India?

Zydus received regulatory approval in India to initiate Phase III clinical trials for one monoclonal antibody, its biotechnology research and development, or Biotech R&D, update says. A monoclonal antibody is the product class specified in the presentation, but Zydus does not name the molecule, target, indication, trial design, planned enrolment, or expected study timetable.

The key change is regulatory permission to start Phase III testing in India, rather than the reporting of Phase III results. This item is distinct from Saroglitazar Magnesium, which Zydus categorises under new chemical entity, or NCE, research, and from FYB206, which is a biosimilar biologics licence application in the United States. The disclosure therefore identifies three different innovation tracks, but provides detailed clinical-stage information for only two of them.

What is the status of Zydus's FYB206 biosimilar filing?

The US Food and Drug Administration, or US FDA, accepted for review the biologics license application, or BLA, for the Pembrolizumab biosimilar FYB206, which Zydus says was developed by partner Formycon AG. Zydus describes it as the first publicly announced Keytruda biosimilar filing accepted for review in the United States, a description that concerns filing acceptance rather than marketing approval.

This US regulatory event differs from the one Indian Phase III clearance because FYB206 has reached BLA review, while the unnamed monoclonal antibody has been cleared only to begin Phase III trials in India. In a separate update, Sentryl Therapeutics entered a licensing agreement with Mereo BioPharma for Alvelestat, a late-stage asset being prepared for Phase III development in alpha-1 antitrypsin deficiency-associated lung disease, or AATD-LD. Zydus did not disclose financial terms of that agreement.

How does the pipeline update fit Zydus's research base?

Zydus reports 10 research and development centres spanning NCEs, active pharmaceutical ingredients, generics, vaccines, biosimilars, wellness and med-tech products. Its company overview also lists about 30,000 employees globally, including more than 1,500 scientists in research and development, providing the scale context for the NCE, Biotech R&D and specialty updates disclosed in 2026.

The research update sits alongside a business with global revenue of more than Rs 26,499 crore in FY26, based on the presentation's assumed exchange rate of Rs 88.33 per US dollar. Yet the presentation does not quantify research spending for the individual Saroglitazar, monoclonal-antibody, FYB206 or Alvelestat programmes. It therefore establishes clinical and regulatory milestones, but not programme-level development cost, future revenue, approval probability, or launch timing.

Conclusion

The combined disclosures show progress at different points of development: completed global Phase II(b) work in MASH, Phase III PBC analysis presented in 2026, Indian permission for one antibody to enter Phase III, and US FDA review acceptance for FYB206. The most concrete distinction is that each milestone has a different regulatory implication, from data generation to filing review.

What to watch next is whether Zydus releases EVIDENCES-X results or outlines a MASH Phase III plan, and whether it identifies the monoclonal antibody's indication and trial timetable. The presentation also leaves the US FDA's review outcome for FYB206 unresolved and says Alvelestat is being prepared for Phase III development in AATD-LD.